SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+31.2%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$1.14B
AUM Growth
+$1.14B
(+26%)
Cap. Flow
-$178M
Cap. Flow
% of AUM
-15.61%
Top 10 Holdings %
Top 10 Hldgs %
37.25%
Holding
104
New
30
Increased
28
Reduced
25
Closed
13
Top Buys
| 1 |
Iovance Biotherapeutics
IOVA
|
$43.7M |
| 2 |
TG Therapeutics
TGTX
|
$38.3M |
| 3 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$23.2M |
| 4 |
Keros Therapeutics
KROS
|
$18.1M |
| 5 |
Biogen
BIIB
|
$15.7M |
Top Sells
| 1 |
Jasper Therapeutics
JSPR
|
$255M |
| 2 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$46.4M |
| 3 |
GSK
GSK
|
$41.1M |
| 4 |
Viking Therapeutics
VKTX
|
$30.3M |
| 5 |
Teva Pharmaceuticals
TEVA
|
$29.3M |
Sector Composition
| 1 | Healthcare | 99.93% |
| 2 | Consumer Staples | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Biogen
BIIB
$19.4B
| $15.7M | 1.17% | +72,800 | New | +$15.7M |
|
27
Krystal Biotech
KRYS
$4.27B
| $15M | 1.11% | 84,100 +44,100 | +110% | +$7.85M |
|
28
Vaxcyte
PCVX
$4B
| $14.2M | 1.05% | 207,750 -207,700 | -50% | -$14.2M |
|
29
BioAtla
BCAB
$26.7M
| $14M | 1.04% | 4,065,197 | – | – |
|
|
30
GSK
GSK
$79.9B
| $13.7M | 1.02% | 319,217 -959,323 | -75% | -$41.1M |
|
31
Rigel Pharmaceuticals
RIGL
$697M
| $13.7M | 1.02% | 9,241,986 -200,593 | -2% | -$297K |
|
32
enGene Holdings
ENGN
$236M
| $13.6M | 1.01% | +800,000 | New | +$13.6M |
|
|
NARI
33
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $13.3M | 0.99% | +277,000 | New | +$13.3M |
|
34
NovoCure
NVCR
$1.38B
| $10.9M | 0.81% | 695,759 +394,759 | +131% | +$6.17M |
|
35
Tango Therapeutics
TNGX
$747M
| $10.7M | 0.8% | 1,350,145 +503,000 | +59% | +$3.99M |
|
36
Applied Therapeutics
APLT
$71M
| $10.6M | 0.79% | 1,564,916 +1,104,123 | +240% | +$7.51M |
|
37
Arcellx
ACLX
$3.85B
| $10.4M | 0.77% | 150,000 -9,000 | -6% | -$626K |
|
38
Enanta Pharmaceuticals
ENTA
$180M
| $10.1M | 0.75% | +580,546 | New | +$10.1M |
|
39
Nuvalent
NUVL
$5.52B
| $9.71M | 0.72% | 129,288 -193,600 | -60% | -$14.5M |
|
40
Immunic
IMUX
$80.9M
| $9.63M | 0.71% | 7,293,007 +6,993,007 | +2,331% | +$9.23M |
|
41
CG Oncology
CGON
$2.04B
| $9.56M | 0.71% | +217,871 | New | +$9.56M |
|
|
INBX
42
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $9.36M | 0.7% | 267,871 +252,871 | +1,686% | +$8.84M |
|
43
Pharvaris
PHVS
$1.39B
| $9.29M | 0.69% | 401,901 +184,505 | +85% | +$4.26M |
|
44
Y-mAbs Therapeutics
YMAB
$388M
| $9.28M | 0.69% | 570,982 +413,800 | +263% | +$6.73M |
|
45
Merus
MRUS
$4.98B
| $8.81M | 0.65% | 195,577 -107,000 | -35% | -$4.82M |
|
46
Syndax Pharmaceuticals
SNDX
$1.41B
| $8.78M | 0.65% | 369,000 -145,000 | -28% | -$3.45M |
|
|
MREO
47
Mereo BioPharma
MREO
$272M
| $8.64M | 0.64% | 2,616,953 -7,160,466 | -73% | -$23.6M |
|
48
Immunovant
IMVT
$2.56B
| $8.55M | 0.63% | 264,650 -52,400 | -17% | -$1.69M |
|
|
THTX
49
Theratechnologies
THTX
$149M
| $7.97M | 0.59% | 4,801,376 | – | – |
|
50
Natera
NTRA
$23.1B
| $7.96M | 0.59% | +87,000 | New | +$7.96M |
|